Aldeyra Therapeutics, Inc.

NasdaqCM:ALDX 株式レポート

時価総額:US$313.2m

Aldeyra Therapeutics マネジメント

マネジメント 基準チェック /24

Aldeyra Therapeuticsの CEO はTodd Bradyで、 Jan2012年に任命され、 の在任期間は 12.83年です。 の年間総報酬は$ 3.68Mで、 15.8%給与と84.2%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の1.94%を直接所有しており、その価値は$ 6.09M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と11.3年です。

主要情報

Todd Brady

最高経営責任者

US$3.7m

報酬総額

CEO給与比率15.8%
CEO在任期間12.8yrs
CEOの所有権1.9%
経営陣の平均在職期間3.8yrs
取締役会の平均在任期間11.3yrs

経営陣の近況

Recent updates

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Jun 21
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Feb 16
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

Nov 06
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Mar 26
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Nov 19
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Dec 22
Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

CEO報酬分析

Aldeyra Therapeutics の収益と比較して、Todd Brady の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$38m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$4mUS$581k

-US$38m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$3mUS$559k

-US$62m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$3mUS$547k

-US$58m

Sep 30 2021n/an/a

-US$53m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$2mUS$544k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$55m

Dec 31 2019US$4mUS$523k

-US$61m

Sep 30 2019n/an/a

-US$58m

Jun 30 2019n/an/a

-US$50m

Mar 31 2019n/an/a

-US$46m

Dec 31 2018US$3mUS$506k

-US$39m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$2mUS$473k

-US$22m

報酬と市場: Toddの 総報酬 ($USD 3.68M ) は、 US市場 ($USD 2.40M ) の同規模の企業の平均を上回っています。

報酬と収益: Toddの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Todd Brady (52 yo)

12.8yrs

在職期間

US$3,684,651

報酬

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Todd Brady
CEO, President & Director12.8yrsUS$3.68m1.94%
$ 6.1m
Stephen Machatha
Chief Development Officer3.8yrsUS$1.59m0.19%
$ 589.0k
Michael Alfieri
Principal Financial & Accounting Officerless than a yearデータなしデータなし
David Burke
Head of Investor Relationsno dataデータなしデータなし
Laura Nichols
Operations Managerno dataデータなしデータなし

3.8yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: ALDXの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Todd Brady
CEO, President & Director19.8yrsUS$3.68m1.94%
$ 6.1m
Richard Douglas
Independent Chair of the Board8.2yrsUS$221.98k0.21%
$ 658.7k
Ben Bronstein
Independent Director14.4yrsUS$190.40k0.048%
$ 148.9k
Gary Phillips
Independent Director15.5yrsUS$194.07k0.025%
$ 78.1k
Martin Joyce
Independent Director11.1yrsUS$195.66k0.040%
$ 126.3k
Neal Walker
Independent Director11.4yrsUS$174.22k0.027%
$ 83.5k
Jay Duker
Member of Retina Segment Scientific Advisory Boardno dataデータなしデータなし
Paul Karpecki
Member of Anterior Segment Scientific Advisory Board4.8yrsデータなしデータなし
John Sheppard
Member of Anterior Segment Scientific Advisory Boardno dataデータなしデータなし
Nancy Miller-Rich
Independent Director4.8yrsUS$174.22k0%
$ 0
Victor Perez
Member of Anterior Segment Scientific Advisory Boardno dataデータなしデータなし
David Chu
Member of Anterior Segment Scientific Advisory Boardno dataデータなしデータなし

11.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: ALDXの 取締役会 は経験豊富で 経験豊富 です ( 11.3年の平均在任期間)。